A recent American Heart Association scientific statement suggests a pragmatic approach in which providers caring for PWH should consider factors such as prolonged viremia, delay in ART initiation, low nadir or current CD4, hepatitis C virus coinfection, and metabolic indices, such as lipodystrophy, when assessing for ASCVD risk [27]. This evidence concerns the gene CD4 and lipodystrophy.